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In recent years, photopharmacology has been gaining momentum as a strategy to optically control biochemical processes.[1](#anie201813110-bib-0001){ref-type="ref"} The use of light as an external trigger to change ligand shape and consequently its pharmacological properties allows the probing of biological systems with great spatiotemporal resolution.[2](#anie201813110-bib-0002){ref-type="ref"} The azobenzene moiety is often used in photoswitchable ligands[1a](#anie201813110-bib-0001a){ref-type="ref"} due to its limited size, high photostability, and tunability of the absorption wavelength *λ* ~max~.[3](#anie201813110-bib-0003){ref-type="ref"} Its thermodynamically stable *trans* isomer typically involves a flat elongated structure, whereas its photoinduced *cis* configuration has a bent geometry with a considerably shorter end‐to‐end distance.[4](#anie201813110-bib-0004){ref-type="ref"} Whereas photopharmacology is well established in the field of enzyme and ion channel modulation, it is an upcoming technology for G protein‐coupled receptors (GPCRs).[1a](#anie201813110-bib-0001a){ref-type="ref"} GPCRs constitute one of the largest families of transmembrane proteins, their dysfunction is associated with a plethora of diseases and consequently GPCRs are one of the most successful classes of drug targets.[5](#anie201813110-bib-0005){ref-type="ref"} Recently, various GPCRs have been successfully targeted using photopharmacology approaches, including μ‐opioid,[6](#anie201813110-bib-0006){ref-type="ref"} CXCR3,[7](#anie201813110-bib-0007){ref-type="ref"} CB1,[8](#anie201813110-bib-0008){ref-type="ref"} H~3~R,[9](#anie201813110-bib-0009){ref-type="ref"} mGlu5,[10](#anie201813110-bib-0010){ref-type="ref"} and GLP1.[11](#anie201813110-bib-0011){ref-type="ref"} Yet, almost all these examples include at least one but more frequently two antagonistic/partial agonist isomeric forms. In contrast, freely diffusible affinity and potency photoswitches in which both isomers act as full agonists are scarce,[1a](#anie201813110-bib-0001a){ref-type="ref"} even though such compounds would be very useful for photopharmacology approaches and complementary to agonist‐to‐antagonist switches.

The histamine H~3~R receptor is an intensively studied GPCR that is known to play an important role in sleep disorders and cognition‐related diseases, such as Alzheimer\'s and Parkinson\'s disease. The first H~3~R antagonist pitolisant (Wakix^®^) has been approved by the European Medicines Agency for the treatment of narcolepsy.[12](#anie201813110-bib-0012){ref-type="ref"} Recently, we published a toolbox of photoswitchable antagonists[9](#anie201813110-bib-0009){ref-type="ref"} that competitively inhibit histamine‐induced H~3~R activity. In the current work, we aimed to develop high‐potency H~3~R photoswitchable agonists that can simplify spatiotemporal studies of the signaling network of the H~3~R. We disclose unique photoswitchable H~3~R agonists that can be optically converted to isomers differing in their affinity and potency.

The scaffold design was inspired by the hH~3~R full agonist VUF5980 previously published by our lab[13](#anie201813110-bib-0013){ref-type="ref"} (Figure [1](#anie201813110-fig-0001){ref-type="fig"}). To date, virtually every published hH~3~R full agonist contains a 4‐substituted imidazole moiety combined with a basic or neutral side chain, as is the case for VUF5980. We left the imidazole portion of the molecule unchanged, and considered the diphenylacetylene moiety to be an attractive candidate for an "azologization" strategy.[3](#anie201813110-bib-0003){ref-type="ref"} Introducing the azobenzene at this position allows for great flexibility in the diversification of the scaffold. Based on the steep structure‐activity relationship observed with VUF5980,[13](#anie201813110-bib-0013){ref-type="ref"} it was postulated that small changes would have significant impact on the affinity and potency for hH~3~R. Therefore, primarily the azobenzene was decorated with small substituents (i.e., methyl and fluorine groups) on both phenyl rings.

![General design and concept of photoswitchable H~3~R full agonists.](ANIE-58-4531-g001){#anie201813110-fig-0001}

To synthesize the ligands, imidazole‐4‐carbaldehyde **2** was protected using *N*,*N*‐dimethylsulfamoylchloride (DMS‐Cl, Scheme [1](#anie201813110-fig-5001){ref-type="fig"}) to afford **3**, which was reduced to **4**. Alcohol **4** was converted to chloride **5** using in situ mesylation. A diverse set of anilines **6**--**15** was oxidized to the corresponding nitrosobenzenes **16**--**25** using Oxone™. After work‐up, they were directly used in a Mills reaction with 3‐amino‐phenylboronic acid pinacol esters **26**--**32** to yield azobenzene--pinacol esters **33**--**48**. Cross coupling with chloride **5** afforded **49**--**64** in generally good yields. Acidic deprotection yielded final compounds **65**--**80**, which were used for biological evaluation.

![General synthetic scheme for photoswitchable H~3~R agonists. See the Supporting Information for detailed experimental procedures.](ANIE-58-4531-g004){#anie201813110-fig-5001}

Compounds **65**--**80** all have *λ* ~max~ values for the π--π\* transition of the *trans* isomer between 313 and 330 nm (Table [1](#anie201813110-tbl-0001){ref-type="table"}). The observed limited variation is due to the absence of strong electron‐donating or ‐withdrawing substituents. Similarly, *λ* ~max~ values for the n--π\* transition of the *cis* isomer differed marginally, ranging between 417 and 430 nm. Upon continuous illumination at 360±20 nm, the values for the photostationary states (PSS) of **65**--**80** ranged from 92.3 to 97.5 % *cis*, except for **69,** which has 82.6 % *cis*. Compounds **65**--**80** all showed slow thermal relaxation at room temperature (20 °C, Table [1](#anie201813110-tbl-0001){ref-type="table"}). The observed thermal relaxation half‐lives were impractically long for direct quantification, therefore extrapolations of high temperature thermal relaxation were used to quantify half‐lives at 20 °C (Table [1](#anie201813110-tbl-0001){ref-type="table"} and Supporting Information, Figure S1).[14](#anie201813110-bib-0014){ref-type="ref"} Compound **69** showed the fastest thermal relaxation in 50 m[m]{.smallcaps} Tris‐HCl pH 7.4 buffer, with a half‐life of 26.6 days, while **72** showed the slowest relaxation, with a half‐life of 147 days.

###### 

Structure‐affinity relationship and photochemical properties of photoswitchable azobenzene‐derived H~3~R agonists. ![](ANIE-58-4531-g005.jpg "image")

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound\                   R^1^                        R^2^           p*K* ~i~\     p*K* ~i~ at PSS\   p*K* ~i~ shift\   *λ* ~max~ *trans* ^\[b\]^\   *λ* ~max~ *cis* ^\[b\]^\   *t* ~1/2~ ^\[c\]^\  PSS^\[d\]^\   
  number                                                               *trans* ± SEM     *cis* ± SEM           ± SEM                  \[nm\]                      \[nm\]                 \[days\]       ± SEM         
  ----------- ------------------------------------ ------------------ --------------- ------------------ ----------------- ---------------------------- -------------------------- -------------------- ------------- ---
  **1**        ![](ANIE-58-4531-g006.jpg "image")   8.74±0.10^\[a\]^        --                --                --                      --                          --                                                

  **65**                       H                           H             8.42±0.04        7.49±0.05         −0.93±0.06                 320                         427                     106          96.1±1.9       

  **66**                      2‐F                          H             8.28±0.08        7.09±0.03         −1.19±0.04                 323                         425                     128          95.7±0.27      

  **67**                      3‐F                          H             8.35±0.09        7.42±0.05         −0.93±0.04                 320                         425                     101          94.1±1.3       

  **68**                      4‐F                          H             7.69±0.08        6.51±0.08         −1.18±0.09                 322                         426                     95.9         95.9±1.6       

  **69**                     2,6‐F                         H             8.00±0.02        7.26±0.09         −0.74±0.10                 313                         417                     26.6         82.6±1.9       

  **70**                      2‐Cl                         H             7.86±0.03        6.85±0.04         −1.02±0.03                 324                         420                     96.1         95.3±0.22      

  **71**                      4‐Cl                         H             6.76±0.07        5.98±0.07         −0.78±0.10                 326                         428                     29.7         97.5±0.48      

  **72**                       H                          2‐Me           5.57±0.09        5.45±0.03         −0.12±0.10                 323                         428                     147          92.3±4.9       

  **73**                       H                          4‐Me           6.90±0.06        5.77±0.13         −1.13±0.08                 327                         430                     42.9         96.3±1.1       

  **74**                       H                          5‐Me           5.75±0.03        5.13±0.17         −0.62±0.19                 322                         427                     122          94.5±1.4       

  **75**                       H                          6‐Me           7.15±0.03        5.94±0.06         −1.21±0.04                 324                         426                     125          95.8±0.92      

  **76**                      2‐Me                         H             7.72±0.03        6.40±0.04         −1.32±0.05                 326                         426                     35.6         96.5±1.6       

  **77**                      3‐Me                         H             7.39±0.08        6.46±0.06         −0.94±0.09                 323                         428                     77.0         95.4±0.39      

  **78**                      4‐Me                         H             5.72±0.14        5.71±0.06         −0.01±0.16                 330                         429                     34.1         94.0±4.4       

  **79**                       H                          4‐F            7.81±0.07        6.54±0.06         −1.27±0.02                 324                         425                     91.7         96.6±0.51      

  **80**                       H                          6‐F            8.39±0.06        7.36±0.03         −1.03±0.03                 322                         427                     84.6         94.6±1.3      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\[a\] Adapted from Wijtmans et al.[13](#anie201813110-bib-0013){ref-type="ref"} \[b\] Determined at 25 μ[m]{.smallcaps} in 50 m[m]{.smallcaps} Tris‐HCl pH 7.4 buffer + 1 % \[D~6~\]DMSO. \[c\] Thermal relaxation half‐life times, as determined by the method of Ahmed et al.[14](#anie201813110-bib-0014){ref-type="ref"} in 50 m[m]{.smallcaps} Tris‐HCl pH 7.4 buffer + 1 % \[D~6~\]DMSO, extrapolating to 20 °C. Arrhenius plots are available in Figure S1 in the Supporting Information. \[d\] Photostationary state area percentages after illumination at 360±20 nm at 1 m[m]{.smallcaps} in \[D~6~\]DMSO and as determined by LC‐MS analysis at 254 nm. All pharmacology experiments were performed at least in triplicate.
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Based on its favorable pharmacological profile (see below) and synthetic tractability, compound **65** was subjected to in‐depth photochemical characterization using ^1^H NMR and LC‐MS analysis during illumination at 360±20 nm. The well‐resolved signal of the benzylic CH~2~ group provided a clear handle for quantification in ^1^H NMR analysis (Figure [2](#anie201813110-fig-0002){ref-type="fig"} A). An overestimation of isomerization percentage is observed in LC‐MS analysis at 254 nm compared to ^1^H NMR analysis (Figure [2](#anie201813110-fig-0002){ref-type="fig"} B and Supporting Information, Table S1), which can be explained by the differences in extinction coefficients for the *trans* and *cis* isomer at 254 nm (Figure [2](#anie201813110-fig-0002){ref-type="fig"} C and Supporting Information, Figures S2 and S3). Compound **65** showed excellent resistance to photobleaching during more than 1000 isomerization cycles (Figure [2](#anie201813110-fig-0002){ref-type="fig"} D). The dynamic isomerization was studied using UV/Vis spectroscopy under alternating illumination (Figure [2](#anie201813110-fig-0002){ref-type="fig"} E). At 25 μ[m]{.smallcaps} of **65** in 50 m[m]{.smallcaps} Tris‐HCl pH 7.4 buffer + 1 % \[D~6~\]DMSO, a half‐life of 4.2±0.16 s for 360±20 nm and 5.7±0.19 s for 434±9 nm was observed.

![A) Representative part of ^1^H NMR spectra of 10 m[m]{.smallcaps} **65** in \[D~6~\]DMSO illuminated at 360±20 nm displayed at various time points (seconds). The presented peak belongs to the hydrogen atoms explicitly drawn in the structure shown above the spectrum. Full spectra are available in Figure S4 in the Supporting Information. B) Representative part of LC‐MS chromatograms belonging to the illuminated NMR sample in Figure 2 A. Full chromatograms are available in Figure S5 in the Supporting Information. C) UV/Vis spectra of 25 μ[m]{.smallcaps} of **65** in 50 m[m]{.smallcaps} Tris‐HCl pH 7.4 buffer + 1 % \[D~6~\]DMSO. PSS *cis* represents a sample which has been illuminated for 300 s using 360±20 nm light. PSS *trans* represents subsequent illumination for 300 s using 434±9 nm light. D) Repeated isomerization of 25 μ[m]{.smallcaps} of **65** in 50 m[m]{.smallcaps} Tris‐HCl pH 7.4 buffer + 1 % \[D~6~\]DMSO analyzed at 320 nm. PSS *cis* was obtained by illuminating **65** for 40 s at 360±20 nm. PSS *trans* was obtained by illuminating **65** for 40 s at 434±9 nm. E) Absorbance at 320 nm of 25 μ[m]{.smallcaps} of **65** in 50 m[m]{.smallcaps} Tris‐HCl pH 7.4 buffer + 1 % \[D~6~\]DMSO. UV/Vis spectra were obtained at 1 s intervals under alternating illumination at 360±20 nm and 434±9 nm perpendicular to the light source of the UV/Vis spectrometer.](ANIE-58-4531-g002){#anie201813110-fig-0002}

The long thermal relaxation half‐lives allowed for detailed pharmacological evaluation using hH~3~R competition binding as well as functional experiments. For this, the compound solutions were either illuminated at 360±20 nm to reach a PSS *cis* or kept in the dark to ensure more than 99 % *trans* isomer. The affinity of both isomers for the hH~3~R was assessed in competition binding with \[^3^H\]‐N^α^‐methylhistamine (NAMH). All compounds displayed hH~3~R binding affinity, which decreased upon illumination, reaching up to a 21‐fold affinity difference in the case of **76**. In terms of absolute affinity, **65** displayed the highest affinities for the hH~3~R with a p*K* ~i~ value of 8.42±0.04 for its *trans* isomer and a p*K* ~i~ value of 7.49±0.05 for its *cis* isomer, resulting in an 8.5‐fold shift upon illumination (Figure [3](#anie201813110-fig-0003){ref-type="fig"} A and Table [1](#anie201813110-tbl-0001){ref-type="table"}). Fluorine‐substituted analogues **67** and **80** performed similarly to **65** in competition binding, displaying only a marginally lower affinity (Table [1](#anie201813110-tbl-0001){ref-type="table"}). Notably, *para*‐methyl substitution on the R^1^ position (**78**) decreased the binding affinity and abrogated the photoisomerization‐induced affinity shift compared to **65** (Table [1](#anie201813110-tbl-0001){ref-type="table"}). Reduction of the size of the *para*‐substituents to either chlorine (**71**) or fluorine (**68**) moieties gradually rescued hH~3~R affinity and reestablished the shift in affinity to 6‐ and 15‐fold, respectively. Methylation at either the *ortho* (**76**) or *meta* (**77**) position of R^1^ still resulted in decent binding affinities and high (21‐fold) to good (8.5‐fold) affinity shifts upon illumination. Addition of substituents at the R^2^ position resulted in a clear affinity cliff, with fluorine substitutions (**79** and **80**) still being allowed, but the addition of a methyl substituent (**72**--**75**) highly decreases the binding affinity of the *cis* isomer. Moreover, for the *trans* isomers, 4‐Me (**73**) and 6‐Me (**75**) substitution was still tolerated yet showed a log‐unit decrease in hH~3~R affinity compared to **65**, while 2‐Me (**72**) and 5‐Me (**74**) groups highly reduced hH~3~R affinity and consequently reduced or even abolished (**72**) the affinity shift (Table [1](#anie201813110-tbl-0001){ref-type="table"}).

![Representative curves of **65** (A) in competition binding with \[^3^H\]‐NAMH or (B) in G~i~ protein activation, as measured by \[^35^S\]‐GTPγS accumulation on HEK293T cell homogenates transiently expressing hH~3~R. Black lines refer to a sample containing more than 99 % *trans* **65**, while magenta lines refer to a sample of **65** illuminated to PSS *cis* with 360±20 nm prior to the assay. C) Schematic drawing of the TEVC setup used for dynamic hH~3~R and GIRK current activation in *Xenopus laevis* oocytes expressing hH~3~R and GIRK. D) Representative part of a GIRK‐mediated current trace during continuous perfusion with 1 μ[m]{.smallcaps} **65**, while illuminating the oocyte with alternating 360±20 and 434±9 nm wavelength, as measured by TEVC. Error bars shown are mean±SD.](ANIE-58-4531-g003){#anie201813110-fig-0003}

Based on the observed affinities and photo‐induced affinity shifts, the efficacy in stimulating hH~3~R‐mediated G~i~ protein activation was evaluated for ligands **65** and **76** in a \[^35^S\]‐GTPγS binding assay. The highest‐affinity ligand **65** (p*K* ~i~ *trans*=8.42±0.04) also displayed the highest potency (pEC~50~ *trans*=7.60±0.13) to induce G~i~ activation, which upon photoisomerization decreased 20‐fold (pEC~50~ at PSS *cis*: 6.30±0.13), with both isomers being full agonists and having intrinsic activities of *α*=1.0±0.03, compared to histamine (Figure [3](#anie201813110-fig-0003){ref-type="fig"} B). Since the observed shift in hH~3~R affinity was 8.5‐fold, the larger (20‐fold) shift in functional potency indicates that for **65** the efficacy (propensity to activate a GPCR[15](#anie201813110-bib-0015){ref-type="ref"}) is also affected upon *trans*--*cis* isomerization. Interestingly, a large photo‐induced decrease in potency of 23‐fold was also obtained for **76** (pEC~50~ *trans*: 6.78±0.11, PSS *cis*: 5.41±0.11, *α*=1.00±0.0). This shift in potency of **76** is completely explained by the observed change of its affinity (see above).

Compound **65** (VUF15 000) was selected as tool compound for further analysis, as it has good synthetic tractability and its superior potency is a clear advantage for pharmacological studies. As the imidazole‐based pharmacophore/scaffold used in the design of these photoswitchable ligands is prone to interact with other histamine receptor subtypes,[13](#anie201813110-bib-0013){ref-type="ref"} **65** was tested for its subtype selectivity. Binding of **65** was more than 300‐fold selective for hH~3~R over hH~1~R and hH~2~R (Supporting Information, Table S2), while a 30‐fold selectivity was observed over its closest homologue hH~4~R (Supporting Information, Table S2). Interestingly, **65** displayed high n[m]{.smallcaps} (*trans*) to low μ[m]{.smallcaps} (PSS *cis*) binding affinities for both mouse and rat H~3~R, with a 4‐fold and 8‐fold shift in binding affinity upon photoisomerization, respectively (Supporting Information, Table S2).

Real‐time photomodulation of hH~3~R activity by **65** was measured using two‐electrode voltage clamp (TEVC) experiments on *Xenopus laevis* oocytes expressing both hH~3~R and G protein‐coupled inwardly rectifying potassium (GIRK)‐channels (Figure [3](#anie201813110-fig-0003){ref-type="fig"} C). In this expression system, histamine application resulted in hH~3~R‐mediated GIRK activation, which was insensitive to optical modulation.[9](#anie201813110-bib-0009){ref-type="ref"} As expected based on our data with the \[^35^S\]‐GTPγS binding assay, *trans*‐**65** elicited an agonistic response in this system, which could be reduced by switching to the less active *cis* isomer upon illumination at 360±20 nm. Retrieval of the agonistic response could be provoked by either actively switching the *cis* isomer back into its *trans* isomer by illuminating at 434±9 nm or by stopping illumination, due to continuous perfusion of the *trans* isomer (Figure [3](#anie201813110-fig-0003){ref-type="fig"} D). Dynamic photoswitching of **65** could be performed repeatedly, illustrating that the use of two specific wavelengths allows optical control of the hH~3~R activation mediated by **65**. Furthermore, photoswitchable agonist **65** showed rapid hH~3~R activation and deactivation kinetics, aiding in its use in in vivo experimentation.

In summary, we have synthesized and characterized 16 photoswitchable hH~3~R agonists that change their affinity and potency upon illumination, indicating a successful azologization strategy. All possess long thermal relaxation half‐lives at room temperature making them useful for a variety of pharmacological studies. Compound **65** (VUF15 000) was selected as key compound on the basis of synthetic tractability and highest absolute hH~3~R affinity. Moreover, upon illumination, **65** displays a high potency and a 20‐fold potency shift, while maintaining full intrinsic activity in G~i~ protein activation, making it especially attractive as a tool compound. With a 20‐fold shift in potency, **65** is one of the best photoswitchable GPCR agonists reported so far. Electrophysiology experiments showed the dynamic optical modulation of hH~3~R activation induced by **65** in real time, setting the stage for further unraveling of the downstream signaling of hH~3~R with great spatiotemporal precision. Recently, photopharmacology approaches with freely diffusible GPCR ligands have, for the first time, been used successfully in vivo to modulate tadpole and zebrafish behavior[10](#anie201813110-bib-0010){ref-type="ref"}, [16](#anie201813110-bib-0016){ref-type="ref"} and to elucidate the role of the metabotropic glutamate receptor 4 in the nervous system using a mouse model of chronic pain.[17](#anie201813110-bib-0017){ref-type="ref"} In view of the widespread distribution of the H~3~R in the central and peripheral nervous system, photopharmacology approaches with tools such as **65** offer new means (complementary to optogenetic approaches[18](#anie201813110-bib-0018){ref-type="ref"}) to investigate the spatial and temporal details of H~3~R modulation of important processes, for example, arousal, cognition and neuropathic pain.[12a](#anie201813110-bib-0012a){ref-type="ref"}--[12e](#anie201813110-bib-0012e){ref-type="ref"}
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